Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04848337 |
|
Recruitment Status :
Recruiting
First Posted : April 19, 2021
Last Update Posted : January 19, 2023
|
Sponsor:
Ulka Vaishampayan
Collaborators:
Merck Sharp & Dohme LLC
University of Michigan
Information provided by (Responsible Party):
Ulka Vaishampayan, Hoosier Cancer Research Network
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 2023 |
| Estimated Study Completion Date : | October 2023 |